Results 131 to 140 of about 1,977,916 (307)

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

open access: yesMolecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker   +16 more
wiley   +1 more source

Nurses' Awareness and Perception of Drug-Drug and Drug Food Interactions

open access: yesEvidence-Based Nursing Research
Context: The issue of drug interactions is a global concern. Studies reported a high prevalence of drug interactions worldwide. The drug-drug interaction (DDIs) and drug-food interactions (DFIs) are often predictable and preventable.
Hend A. E. Elshenawi   +1 more
doaj   +1 more source

Supplementary Material for: Vincristine-Induced Seizure from Drug Interactions: A Case Report and Review of Literature

open access: gold, 2023
Michael J. Texada   +7 more
openalex   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

open access: yesMolecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad   +17 more
wiley   +1 more source

Prevalence of Potential Drug-drug Interactions among Psychiatric Patients at Psychiatry Hospital in Sulaimani City

open access: yesAl-Mustansiriyah Journal of Pharmaceutical Sciences
Background: Clinically significant drug-drug interactions can be defined as events in which the pharmacodynamics or pharmacokinetic characteristics of a drug are modified by coadministration of a second drug to the patient’s medication protocol, which ...
Raz Muhammed HamaSalih   +4 more
doaj   +1 more source

A novel Malonamide Periodic Mesoporous Organosilica (PMO) for controlled Ibuprofen release [PDF]

open access: yes, 2015
Controlled drug release gained a sharply increasing interest over recent years. Multiple materials have been screened as possible drug carriers, ranging from biodegradable polymers to hydroxyapatite[1].
Clerick, Sander   +5 more
core  

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

open access: yesMolecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang   +8 more
wiley   +1 more source

Food-Drug Interactions

open access: yesOman Medical Journal, 2011
The effect of drug on a person may be different than expected because that drug interacts with another drug the person is taking (drug-drug interaction), food, beverages, dietary supplements the person is consuming (drug-nutrient/food interaction) or ...
Arshad Yar Khan   +2 more
doaj  

Screening for lung cancer: A systematic review of overdiagnosis and its implications

open access: yesMolecular Oncology, EarlyView.
Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz   +12 more
wiley   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

open access: yesMolecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy